Shuangcheng Pharmaceutical released its 2026 interim report on August 22, 2026. The company's total operating revenue was 117 million yuan, net profit attributable to the parent company was 13.6278 million yuan, and net cash inflow from operating activities was 20.5123 million yuan. The company's latest asset-liability ratio was 47.02%, gross margin was 55.61%, down 6.75 percentage points from the previous quarter, and latest return on equity was 3.20%. The company's diluted earnings per share was 0.03 yuan, total asset turnover was 0.14 times, and inventory turnover was 0.69 times. The company had 38,700 shareholders, and the top ten shareholders held 217 million shares, accounting for 52.40% of total share capital.
Hainan Shuangcheng PharmaceutInterim report shows net profit of 13.6M yuan, but no comparative figures or market expectations provided.
